FDA-approved GHRH analog · visceral fat and growth hormone axis
Tesamorelin is a stabilized GHRH analog (44 aa) — the only growth hormone secretagogue approved by the FDA (Egrifta). It stimulates your own GH in a pulsatile way, preserving natural IGF-1 feedback.
Its FDA-approved flagship use: reduces visceral abdominal fat (−15–18% VAT in trials) — the fat that wraps around your organs.
Raises GH and IGF-1 pulsatilely, not flat. Preserves IGF-1 feedback, unlike exogenous growth hormone.
Reduces hepatic fat (signal in NAFLD) and provides a modest improvement in lean mass and body composition.
A trial in older adults showed better executive function. Nocturnal GHRH also supports sleep quality.
Tesamorelin pairs well with metabolic and recovery pathways different from its own. Never with CJC-1295 (dual GHRH, redundant).
If you have pre-diabetes or diabetes, monitor glucose and insulin — Tesamorelin can raise them. Consult your physician before combining.
Tesamorelin is a stabilized synthetic analog of GHRH (growth hormone–releasing hormone, 44 amino acids) and is the only FDA-approved GH secretagogue (brand name Egrifta). Instead of injecting growth hormone directly, it asks your own pituitary to release it — pulsatilely and preserving natural IGF-1 feedback.
SuperBio Labs Tesamorelin is supplied as lyophilized powder with verified HPLC ≥99% purity. Each lot ships with an independent Certificate of Analysis confirming identity by LC-MS, peptide content (98–102%), and endotoxin levels (<1.0 EU/mg).
Its flagship lane, with high evidence (phase III trials in ~816 patients), is the reduction of visceral abdominal fat (−15–18% VAT). Beyond that, there are signals in hepatic fat/NAFLD (Lancet HIV 2019) and in executive function in older adults (Arch Neurol 2012). In body composition the lean-mass contribution is modest — this is not a peptide for building muscle. Honest caveat: much of the evidence comes from specific populations (HIV and older adults).
Within our catalog, Tesamorelin holds the GH-axis slot: it gains credibility (FDA) and a lane of its own (visceral fat), but it does not build muscle nor provide the ghrelin/sleep arm of an Ipamorelin.
Informed professional research use only.
Each order includes everything needed for the cycle. No separate purchases required.
This product meets all five — your batch COA ships with the kit.
Conservative protocol included in the kit. If you have pre-diabetes, diabetes, or raised IGF-1, consult your physician before starting.
Abdominal/visceral adiposity · FDA-approved flagship use.
Raise GH and IGF-1 physiologically and pulsatilely, without exogenous GH.
NAFLD · signal of reduced hepatic fat in trials.
Preserve lean mass during weight loss (not glucose).
Executive function in older adults · real trial.
Nocturnal GHRH · supports deep-sleep quality.
Generally well tolerated, but with clear monitoring. This is not a harmless peptide: it has real contraindications.
It raises IGF-1 (monitor with labs) and can raise glucose/insulin — caution in pre-diabetes and diabetes. It may cause fluid retention and arthralgia (joint pain). Contraindicated in active cancer, pituitary disease, and pregnancy. For athletes: it is on the WADA list (S2.2.4). Never combine it with CJC-1295 (both are GHRH).
| Product | Tesamorelin |
| CAS Number | 218949-48-5 |
| Molecular Weight | 5135.9 Da |
| Purity (HPLC) | ≥99% |
| Format | Lyophilized powder |
| Quantity | 20mg per vial |
| Class | GHRH analog (44 aa) |
| Endotoxins | <1.0 EU/mg |
| Storage | −20 °C, protected from light |
| Use | Use under professional judgment |